Bulevirtide Continues to Show Promise for People With Hepatitis D
The entry inhibitor bulevirtide (Hepcludex) led to reductions in hepatitis delta virus (HDV) viral load, liver enzyme levels and liver fibrosis, improving on earlier results, according to study findings presented last week at the International Liver Congress (ILC 2022) in London. Another study of real-world bulevirtide use in France also showed virological and biochemical improvements.